Development of a Multi-biomarker Prognostic Risk Score for IPF Based on Serum Proteins

Learn how the Prognostic Lung Fibrosis Consortium (PROLIFIC) developed and validated a novel four-protein biomarker risk score to predict disease progression in idiopathic pulmonary fibrosis (IPF). In this presentation, Dr. Peter Schaefer shares the scientific approach, clinical validation process, and potential impact of this biomarker-based tool for improving patient stratification and accelerating pulmonary fibrosis drug development.

What you'll gain from watching this video:

• Understand the science behind the biomarker panel and how four serum proteins were selected from years of IPF biomarker research.

• See how the prognostic risk score was developed and validated using real-world patient registry data and clinical trial samples.

• Explore the potential impact on clinical trials and drug development, including patient stratification, biomarker qualification, and future applications in pulmonary fibrosis research.

   

Complete the form below to access this video.